替比夫定对HBeAg（＋）慢性乙型肝炎患者CD4＋CD25＋CD127low／－调节性T细胞的影响

摘要

目的：研究替比夫定（TBV）对HBeAg（＋）慢性乙型肝炎（CHB）患者CD4＋CD25＋CD127low／－调节性T细胞（Treg）的影响。方法：筛选健康志愿者和HBeAg（＋）CHB患者各35例作为对照组和试验组。流式细胞技术测对照组和试验组TBV治疗前后外周血CD4＋CD25＋CD127low／－Treg占总淋巴细胞比例（下称“Treg比例”），分析Treg变化。结果：治疗前试验组Treg比例（12．55±1．78）％高于对照组（8．32±1．00）％（P＜0．05）；治疗12、24、36及48周后Treg比例依次为（10．42±1．04）％、（9．55±0．74）％、（8．78±0．67）％和（8．74±0．71）％，逐渐降低，除48周外，各Treg比例与前一时间点比较，差异均有显著性（P＜0．05）。结论：HBeAg（＋）CHB患者Treg比例升高，经替比夫定治疗后下降。%Objective To study the effect of telbivudine (TBV) on the ratio of CD4+ CD25+CD127low/-regulatory T cell (Treg) of HBeAg-positive chronic hepatitis B (CHB). Methods The ratios of Treg before and after treatment for 12, 24, 36 and 48 weeks with TBV of thirty-five patients with HBeAg-positive CHB were detected. Results Ratios of Treg were (12.55 ± 1.78)%, (10.42 ± 1.04)%, (9.55 ± 0.74)%, (8.78 ± 0.67)%, (8.74 ± 0.71)%respectively before and after treatment of 12, 24, 36 and 48 weeks and all the values were lower than its former one (P < 0.05), except the 48 weeks′. Conclusions The ratio of Treg of HBeAg (+) CHB decreases after treatment with TBV.